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KEY POINTS 31 
 32 
Question: Does routine prophylactic low-dose oxygen supplementation after acute stroke improve 33 
functional outcome? 34 
 35 
Findings: In this randomized clinical trial 8003 patients with acute stroke were allocated within 24 36 
hours of admission to 3 days of continuous oxygen, nocturnal oxygen, or control. After 3 months 37 
there was no significant difference in death and disability for the combined oxygen groups 38 
compared with control (odds ratio 0.97), or for continuous oxygen compared with nocturnal oxygen 39 
(odds ratio 1.03).  40 
 41 
Meaning: Routine low-dose oxygen did not improve outcomes in non-hypoxic patients after acute 42 
stroke.  43 
44 
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ABSTRACT  45 
Importance: Hypoxia is common in the first few days after acute stroke, frequently intermittent, 46 
and often undetected. Oxygen supplementation could prevent hypoxia and secondary neurological 47 
deterioration and thus has the potential to improve recovery.  48 
Objective: To assess whether routine prophylactic low-dose oxygen therapy is superior to control 49 
in reducing death and disability at 90 days and, if so, whether oxygen given at night only, when 50 
hypoxia is most frequent, and oxygen administration is least likely to interfere with rehabilitation, is 51 
more effective than continuous supplementation. 52 
Design, setting, and participants: In this single-blind randomized clinical trial 8003 adults with 53 
acute stroke were enrolled from 136 participating centers within 24 hours of hospital admission, if 54 
they had no clear indications for, or contraindications to, oxygen treatment (first patient enrolled 24-55 
Apr-2008, last follow-up 27-Jan-2015).  56 
Interventions: Participants were randomized 1:1:1 to continuous oxygen for 72 hours (n=2668), 57 
nocturnal (21:00-07:00) oxygen for three nights (n=2667), or control (oxygen only if clinically 58 
indicated, n=2668). Oxygen was given via nasal tubes at 3L/min if baseline oxygen saturation was 59 
≤93% and at 2L/min if >93%.  60 
Main outcomes and measures: The primary outcome was the modified Rankin Scale (mRS) score 61 
(a measure of disability ranging from 0=no symptoms to 6=death, minimum clinically important 62 
difference 1 point), assessed at 90 days by postal questionnaire (participant aware, assessor 63 
blinded). The mRS was analyzed by ordinal logistic regression, which yields a 'common' odds ratio 64 
(OR) for a change from one disability level to the next better (lower) level; OR > 1.00 indicates 65 
improvement. Significance was set at p≤0.05 for the primary outcomes and≤ 0.01 for all other 66 
outcomes. 67 
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Results: 8003 patients (4398 (55%) males, mean age 72 (SD13) years; median NIHSS 5; mean 68 
baseline oxygen saturation 96.6%) were enrolled. The primary outcome was available in 7677 69 
(96%) participants. The unadjusted odds ratio for a better outcome (calculated via ordinal logistic 70 
regression) was 0.97 (95% CI 0.89–1.05), p=0.47 for oxygen versus control, and 1.03 (95% CI 71 
0.93–1.13), p=0.61 for continuous versus nocturnal oxygen. No subgroup could be identified that 72 
benefited from oxygen. There were 348 (13.0%), 294 (11.0%), and 322 (12.1%) participants with at 73 
least one serious adverse event in the continuous, nocturnal, and control groups respectively. No 74 
significant harms were identified.  75 
Conclusions and relevance: Among non-hypoxic patients with acute stroke the prophylactic use of 76 
low-dose oxygen supplementation did not reduce death or disability at 3 months. These findings do 77 
not support low-dose oxygen in this setting.  78 
Trial Registration: ISRCTN52416964 79 
Funder: Research for Patient Benefit Programme and Health Technology Assessment Programme, 80 
National Institute for Health Research, UK 81 
82 
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INTRODUCTION  83 
Hypoxia is common during the first days after an acute stroke,
1
 and associated with higher rates of 84 
neurological deterioration,
2
 death and institutionalization,
3 
and greater mortality.
4
 While cells in the 85 
ischemic penumbra are only viable for a few hours, brain cells beyond the ischemic core and 86 
penumbra remain at risk of delayed cell death for several days owing to vasogenic edema, 87 
inflammation, and programmed cell death, particularly if metabolic disturbances are compounded 88 
by hypoxia.
5,6,7
 Continuous monitoring is associated with better outcomes,
8
 but even in intensively 89 
monitored patients, hypoxia is not always identified and treated. Adverse outcomes were observed 90 
to be increased when only some desaturations <90% were treated with oxygen, and reduced when 91 
all were treated.
3
 92 
Supplemental oxygen could improve outcomes by preventing hypoxia and secondary brain damage, 93 
but could also have adverse effects.
9 
These include vasoconstriction and pulmonary toxicity with 94 
high concentrations,
9 
respiratory tract infection due to contamination of the giving set, the tubing 95 
acting as an impediment to mobilization, stress, and the direct effects of oxygen on vascular tone 96 
and blood pressure.
10
 Three small trials of short-term (≤12 hours), high-flow (10-45 L/min) 97 
therapeutic oxygen, aimed at generating supra-physiological blood oxygen levels, have not shown 98 
improved outcomes. 
11,
 
12, 13
 A larger trial (n=550) using low-dose supplemental oxygen (3 L/min 99 
for 24 hours) also showed no benefit,
14
 but early neurological recovery was improved in a study 100 
giving low-dose oxygen over 72 hours.
15 
 101 
The primary aim of the Stroke Oxygen Study (SO2S) was to determine whether low-dose oxygen 102 
therapy during the first 3 days after an acute stroke improves outcome compared to usual care 103 
(oxygen only when needed). As oxygen may restrict mobility and interfere with daytime activities, 104 
the secondary hypothesis was that oxygen given at night only, when hypoxia is most likely, is more 105 
effective than continuous oxygen supplementation. 106 
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 107 
METHODS  108 
Study design  109 
This was a multi-center randomized clinical trial of oxygen supplementation with single-blind 110 
outcome assessment. The protocol (see online supplement),
16
 statistical analysis plan (see online 111 
supplement),
17
 and data collection forms
18
 are published. Fully informed written or witnessed oral 112 
consent was given by the participants or, if they did not have capacity to consent, by a legal 113 
representative. The protocol was approved by the North Staffordshire Research Ethics Committee 114 
(06/Q2604/109).  115 
Participants  116 
Adults (≥18 years) with a clinical diagnosis of acute stroke (see eText 1 for definition) within 24 h 117 
of hospital admission, who had no clinical indications for, or contraindications to, oxygen 118 
treatment, or any concomitant condition likely to limit life expectancy to <12 months were eligible.  119 
Randomization and interventions  120 
Participants were allocated 1:1:1 via central web-based minimized randomization
19
 to one of three 121 
groups: i) continuous oxygen supplementation, ii) nocturnal oxygen supplementation only, iii) no 122 
routine oxygen (control). The factors for which imbalances were minimized were: the ‘six simple 123 
variables’ (SSV) prognostic index for independent survival at 6 months20 (cut-offs ≤0.1, >0.1 to 124 
≤0.35, >0.35 to ≤0.70, >0.70), oxygen treatment before randomization (yes, no, unknown), baseline 125 
oxygen saturation on air (<95, ≥95%), and time since stroke onset (defined as the last time well for 126 
wake-up strokes) (≤3, >3 to ≤6, >6 to ≤12, >12 to ≤24, >24 hours). No blocking was used. Oxygen 127 
was administered per nasal tubes either continuously (day and night) during the first 72 h after 128 
randomization or overnight (21:00–07:00) for three nights. Oxygen was given at a flow rate of 3 129 
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L/min if baseline saturation was 93% or below, or at a flow rate of 2 L/min, if baseline saturation 130 
was greater than 93%. In the control group no routine oxygen supplementation was given. 131 
Vital signs were observed at least 6-hourly, with any abnormal findings treated independently of 132 
trial allocation. Patients requiring oxygen in the control group, or in the nocturnal oxygen group 133 
during the day, or needing changes in oxygen dosage for clinical reasons, were given the 134 
appropriate concentration of oxygen irrespective of treatment group. In addition, for 4144 patients 135 
recruited in the latter half of the study, spot checks of treatment adherence were undertaken at 136 
midnight and 6 am. 137 
Outcomes and blinding 138 
Outcomes were assessed at one week by a member of the local research team and at 90 days via 139 
postal questionnaire. Telephone interviews were conducted with non-responders, or to clarify 140 
unclear or missing answers. The primary outcome was the modified Rankin Scale (mRS)
 21
 score (a 141 
measure of disability ranging from 0=no symptoms to 6=death; minimum clinically important 142 
difference 1 point) at 90 days. Secondary outcomes were: number of participants with neurological 143 
improvement, defined as a ≥4-point decrease on the National Institutes of Health Stroke Scale 144 
(NIHSS)
22, 23 
between randomization and day 7, the highest and lowest oxygen saturations within 145 
the first 72 h, and mortality at one week. Further secondary outcomes at 90 days were: mortality, 146 
number of participants alive and independent (mRS≤2), number of participants living at home, 147 
Barthel Index (BI) activities of daily living (ADL) score,
24
 quality of life (EuroQol EQ5D-3L),
25
 148 
and Nottingham Extended Activities of Daily Living (NEADL) score.
26
 For the NIHSS and BI, 149 
deaths were recorded as the worst outcome on the scale.
27
 Participants, their doctors, and local 150 
research staff who recorded the one-week outcomes were not blind to the study interventions. 90-151 
day assessments were undertaken by the SO2S study office blind to treatment allocation.  152 
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Study size 153 
The initial recruitment target was 6,000 participants, which was estimated to provide 90% power to 154 
detect small (0.2 mRS-point, e.g. a one-point improvement in one in 5 participants) differences 155 
between oxygen (continuous and night only groups combined) and no oxygen at p≤0.01, and 90% 156 
power at p≤0.05 to detect small differences between continuous oxygen and oxygen at night only. 157 
The study size was subsequently revised to 8,000 participants, using ordinal methods,
16,17
 without 158 
knowledge of interim results, to increase the number of patients with severe strokes and thereby 159 
provide greater power to investigate any differential effectiveness of oxygen versus control within 160 
subgroups (defined by severity).  161 
Statistical analysis  162 
The trial was designed to answer two key questions: firstly, whether oxygen supplementation 163 
improves outcome (mRS at 90 days) and secondly, whether giving oxygen at night is more effective 164 
than giving it continuously. The main comparisons therefore were of the two combined oxygen 165 
groups (continuous and night-time only) versus control, and of continuous oxygen versus oxygen at 166 
night only. The statistical analysis plan describes the analysis methods in detail (see online 167 
supplement).
17
 168 
The mRS was analysed by ordinal logistic regression, which yields a ‘common’ odds ratio (OR) for 169 
a move from one level to the next better (lower) level with an odds ratio more than 1.00 indicating 170 
an improvement. For this and other outcome variables, a primary unadjusted analysis and a 171 
secondary covariate-adjusted analysis were performed. Adjusted analyses incorporated the 172 
following covariates: age, sex, baseline NIHSS score, baseline oxygen saturation, and the SSV 173 
prognostic index for 6-month independence (or for analysis of mortality, the SSV prognostic index 174 
for 30-day survival). Sensitivity analysis for the mRS used multiple imputation of missing values 175 
(using a chained equations method, with 20 imputed datasets). Additional imputations were 176 
performed to allow for the possibility that data were missing not at random and were either i) better 177 
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or ii) worse than expected; missing values were thereby replaced by either very good (i.e. lowest) or 178 
very poor (i.e. highest) scores on the mRS, as appropriate (see eTable 3 in supplementary 179 
appendix). Subgroups, for the mRS only, were analysed by an interaction term, and were predefined 180 
in the statistical analysis plan
17
 (see figure 2 for details of subgroups). 181 
For continuous outcomes, means and standard deviations (SD) or medians and interquartile ranges 182 
(IQR) are reported, as appropriate. Unadjusted analyses used unrelated t-tests, with the mean 183 
difference between treatments and corresponding confidence interval (CI) reported. The adjusted 184 
analysis used analysis of covariance, with the covariates specified earlier included in the analysis. 185 
For dichotomous outcomes, percentages were compared across the treatment comparisons using a 186 
chi-squared test (unadjusted analyses). Adjusted analyses of dichotomous outcomes used binary 187 
logistic regression, with the covariates listed earlier; ORs and confidence intervals are reported.  188 
All analyses were by intention to treat, i.e. according to the treatment group to which participants 189 
were allocated, irrespective of treatment actually received. Statistical significance was set at p≤0.05 190 
with 95% CIs for the primary outcome and at p≤0.01 with 99% CIs for secondary outcomes. All 191 
reported p-values are 2-sided. The main analysis was performed in SAS® software for Windows, 192 
version 9.4, SAS Institute Inc., Cary, USA. IBM SPSS for Windows version 22, Armonk, New 193 
York, USA was used for sensitivity analyses. 194 
Interim analyses of safety and effectiveness were reviewed annually by an independent Data 195 
Monitoring and Safety Committee. No alpha-spending adjustments were made.  196 
 197 
RESULTS 198 
Participants 199 
8003 participants from 136 collaborating centers in the UK were randomized and followed up 200 
between April 24
th
 2008 and January 27
th
 2015 (Figure 1). Baseline demographic and clinical 201 
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characteristics, including stroke severity and oxygen saturation at randomization, were well 202 
balanced in the three groups (Table 1). The mean age of participants was 72 (SD 13) years, 4398 203 
(55%) were male, and 7332 (92%) could undertake activities of daily living independently before 204 
the stroke. The mean/median NIHSS was 7/5 (SD 6/IQR 3-9). 1601 (20%) had been given oxygen 205 
prior to randomization, in the ambulance or in hospital. Patients were enrolled at a median 206 
20h:43min (IQR 11:59–25:32) after symptom onset. The mean oxygen saturation at randomization 207 
was 96.6% (SD 1.7%). All participants had a clinical diagnosis of stroke at the time of enrolment. 208 
The final diagnosis at 7 days was ischemic stroke in most cases (n=6555, 82%), 588 (7%) had a 209 
primary intracerebral hemorrhage, and 294 (4%) were strokes without CT diagnosis. 168 (2%) were 210 
given a final diagnosis of transient ischemic attack, and 292 (4%) were found to have other non-211 
stroke diagnoses, with missing data in 106 (1%). 212 
6991 (87%) of participants gave fully informed consent and 1012 (13%) had consent given by a 213 
relative, carer, or an independent legal representative (eTable 1). Of the participants who were 214 
unable to consent themselves and were included by a representative, 6 (0.1%) refused consent at the 215 
1-week reassessment and 22 (2%) at the 90-day assessment, and were withdrawn.  216 
Treatment adherence 217 
Adherence was similar in the continuous and night-time oxygen groups, with 2158 (81%) and 2225 218 
(83%), respectively, prescribed oxygen for the full course of treatment (eTable 2). 433 (16%) 219 
participants in the continuous and 361 (14%) in the night-time group discontinued oxygen 220 
prematurely. The most common reason for early discontinuation of oxygen was discharge from 221 
hospital. In the control group, trial oxygen was recorded as being given in 33 (1.2%), with no 222 
recording of whether oxygen was given in 406 (15%).  223 
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Effect on oxygenation 224 
Oxygen treatment resulted in a significant increase of 0.8% and 0.9% in the highest and lowest 225 
oxygen saturations, respectively, during the 72 h of the intervention period in the continuous 226 
oxygen group compared to controls, and of 0.5% and 0.4% for the highest and lowest oxygen 227 
saturations, respectively, in the nocturnal oxygen group compared to controls (p<0.001 for all 228 
comparisons, Table 2). Significantly more participants in the combined oxygen groups required 229 
oxygen for clinical reasons during the intervention period than in the control group: 9% (463) vs. 230 
7% (176), p<0.001. Similarly, more participants in the continuous than nocturnal oxygen group 231 
required oxygen: 10% (254) vs. 8% (209), p=0.03. 232 
Main outcome 233 
The primary analysis demonstrated that oxygen supplementation did not significantly improve 234 
functional outcome at 90 days (Figure 2). The unadjusted OR for a better outcome (lower mRS) 235 
was 0.97 (95% CI 0.89–1.05, p=0.47) for combined oxygen versus control, and 1.03 (95% CI 0.93–236 
1.13, p=0.61) for continuous oxygen versus nocturnal oxygen. Secondary analyses adjusted for age, 237 
sex, baseline NIHSS score, baseline oxygen saturation, and the SSV prognostic index yielded very 238 
similar results: OR=0.97 (95% CI 0.89–1.06, p=0.54) for the combined oxygen group versus 239 
control and OR=1.01 (95% CI 0.92–1.12, p=0.81) for continuous oxygen versus oxygen at night 240 
only. With similar numbers of missing responses in the continuous oxygen (n=101), nocturnal 241 
oxygen (n=106), and control groups (n=119), findings were much the same in sensitivity analyses 242 
using multiple imputation or analyzing adherers only (eTable 3).  243 
Subgroup analysis (figure 3) found no indication that treatment effectiveness differed in any of the 244 
predefined subgroups, even those where most benefit might be expected – such as patients with 245 
more severe strokes or those for whom oxygen supplementation was started early after onset of 246 
stroke.  247 
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Secondary outcomes 248 
Analyses of secondary outcomes also showed no benefit from oxygen (Table 2). Neurological 249 
impairment at one week improved from baseline to the same degree in all three groups, with median 250 
NIHSS scores of 2 (IQR 1–6) by one week. Oxygen treatment did not increase the number of 251 
participants who were alive and independent, or back in their home, the ability to perform basic (BI) 252 
or extended (NEADL) activities of daily living, or quality of life (EQ5D-3L) at 90 days. The results 253 
remained unchanged after adjustment for baseline prognostic factors (eTable 4). Mortality (figure 4) 254 
was similar in the oxygen (both groups combined) and control groups (hazard ratio [HR] =0.97 255 
[99% CI 0.78–1.21], p=0.75), and for continuous oxygen versus oxygen at night only (HR=1.15 256 
[99% CI 0.90–1.48], p=0.15).  257 
Exploratory analyses 258 
There was no evidence of increased stress levels (higher heart rates, higher blood pressure and need 259 
for sedation) in oxygen-treated participants than in controls, or that oxygen treatment was 260 
associated with more infections, with little differences in the highest temperature or the need for 261 
antibiotics (Table 2). 262 
Safety outcomes 263 
The number of serious adverse events by 90 days was similar in the combined oxygen and control 264 
groups, but lower in the nocturnal oxygen group when compared to continuous oxygen (Table 2 and 265 
eTable 5). No oxygen-related adverse events (respiratory depression, drying of mucous membranes) 266 
were reported.  267 
 268 
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DISCUSSION 269 
The key finding of this trial is that routine prophylactic low-dose oxygen supplementation did not 270 
improve outcome in patients with acute stroke who were not hypoxic at baseline, whether given 271 
continuously for 72 hours or at night only. This applied to the primary 90-day functional outcome 272 
and to all other tested outcomes, including early neurological recovery, mortality, disability, 273 
independence in basic and extended activities of daily living, and quality of life. The results 274 
remained unchanged in analyses adjusted for baseline prognostic factors, and in sensitivity analyses 275 
using multiple imputation or analyzing adherers only. Subgroup analyses did not identify any 276 
characteristics that would make a patient more likely to benefit from oxygen treatment. This 277 
includes enrolment between 3-6 hours after onset, patients with a lower baseline oxygen saturation, 278 
severe strokes, a reduced level of consciousness, and a history of heart failure or lung disease; i.e. 279 
those characteristics for which benefit from oxygen was most anticipated. Because of the large 280 
overall size of this trial, these patient subgroups were each sufficiently large for the lack of 281 
observed benefit to be likely real and not a false negative.  282 
In contrast to the much smaller SOS Pilot study,
15
 this trial showed no evidence of better early 283 
neurological recovery with oxygen. Subgroup analysis of an earlier study of low-dose oxygen 284 
supplementation in acute stroke
14
 suggested that oxygen might adversely affect outcome in patients 285 
with mild strokes, possibly through formation of toxic free radicals. A more recent study of short-286 
burst high-flow oxygen (45L/min) was terminated early after enrolment of 85 patients because of 287 
excess mortality in the actively treated group.
13
 Hyperoxia was independently associated with 288 
mortality in a large retrospective cohort study of ventilated patients with stroke.
28
 While suggestive 289 
of potential harm, these findings could be due to confounding factors. This trial showed no 290 
difference in mortality, functional outcomes and adverse events and therefore provides reassuring 291 
evidence that low-dose oxygen supplementation is safe in patients with acute stroke. 292 
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As a large pragmatic trial, this study included patients with a clinical diagnosis of acute stroke, 293 
without radiological confirmation. The sample therefore included ischemic and hemorrhagic 294 
strokes, and participants who were later found to have mimics or transient ischemic attacks.  295 
This trial was a large pragmatic study aimed at unselected patients with stroke. Over half of all 296 
acute stroke services in the UK participated and wide inclusion criteria allowed enrolment of a 297 
representative sample of ischemic and hemorrhagic patients with stroke across the whole range of 298 
severity. Stroke severity was similar to that of the UK stroke population as a whole, with a median 299 
NIHSS of 5 in this trial and 4 in the UK Sentinel Stroke National Audit Programme, which includes 300 
every stroke patient admitted to UK hospitals.
31
 The median NIHSS of 127,950 patients with acute 301 
ischemic stroke in the US Get with the Guidelines Register
32
 was 5, as in this trial. A median 302 
NIHSS of 5 at baseline was also recorded in a large Dutch study of antibiotic prophylaxis after 303 
stroke, with similarly wide inclusion criteria.
33 
304 
This study has several limitations. Minor benefits from oxygen treatment might have been masked 305 
by poor compliance. However, this seems unlikely given the high statistical power to detect even 306 
small improvements. Moreover, sensitivity analyses did not show better outcomes in the adherers-307 
only group (eTable 3). Furthermore, this trial found significant increases in the oxygen saturations 308 
in the treated groups compared to control. Patients with acute stroke are often restless and confused. 309 
Ensuring full adherence would ideally require 1:1 nursing. However, this is not possible outside an 310 
intensive care setting. The main outcome was assessed by postal questionnaire, supported by 311 
telephone interviews in non-responders. This method has been used successfully in large pragmatic 312 
trials,
29,30
 but has been replaced by remote multiple-rater video-recorded interviews or in-person 313 
interview and examination by an allocation-blinded rater using formal structured assessments in 314 
several more recent studies. Low-dose oxygen supplementation may not be sufficient to prevent 315 
severe desaturations; both the SOS Pilot
15 
and this trial found no significant difference in severe 316 
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desaturations between the treatment and control groups.
 
A small (n=46) non-randomized study 317 
comparing high-flow oxygen treatment via mask with low-flow supplementation via nasal cannulae 318 
showed a trend towards lower mortality with high flow. However, evidence from randomized trials 319 
of high-flow oxygen treatment in acute stroke
11,12,13
 does not show that higher doses of oxygen are 320 
associated with better outcomes. Early administration of high-dose oxygen might help maintain the 321 
viability of the ischemic penumbra and allow a broader time window for neuroprotection or 322 
thrombolysis. This question was not addressed in this trial of prophylactic oxygen, but will be 323 
tested in the PROOF trial (http://www.safestroke.eu/proof-trial/).   324 
The median time from stroke onset to randomization in this trial was 20h 43min. However, 101 325 
participants were enrolled early (within 3 hours of symptom onset). Subgroup analysis (figure 3) 326 
showed a similar lack of effect for oxygen in the small subset of patients enrolled early as in those 327 
enrolled later, but was underpowered. Larger trials in the early time window would be needed to 328 
definitely exclude a benefit.  329 
Conclusions  330 
Among non-hypoxic patients with acute stroke the prophylactic use of low-dose oxygen 331 
supplementation did not reduce death or disability at 3 months. These findings do not support low-332 
dose oxygen in this setting. 333 
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TABLES  582 
 583 
Table 1 Baseline characteristics 584 
 585 
 Continuous oxygen 
n=2668 
Nocturnal oxygen 
n=2667 
Control n=2668 
Demographic characteristics 
Age; (years); mean (SD)
a
    72 (13) 72 (13) 72 (13) 
Male sex; n (%) 1466 (55) 1466 (55) 1466 (55) 
Prognostic factors 
Living alone before the stroke; n (%)
a
  861 (32) 857 (32) 907 (34) 
Independent in basic ADLs before the stroke; n (%)
a
  2451 (92) 2431 (91) 2450 (92) 
Normal verbal response; n (%)
a
 2190 (82) 2207 (83) 2196 (82) 
Able to lift both arms; n (%)
a
  1998 (75) 2022 (76) 1996 (75) 
Able to walk; n (%)
a
  660 (25) 704 (26) 677 (25) 
Probability of 30-day survival; median (IQR)
 20
 0.92 (0.86-0.95) 0.92 (0.86-0.95) 0.92 (0.86-0.95) 
Alive and independent at 6 m; probability median (IQR)
 a 20
  0.44 (0.12-0.71) 0.42 (0.12-0.71) 0.42 (0.12-0.71) 
Blood glucose; mg/dl mean (SD) 127 (46) 126  (43) 128 (45) 
Concomitant medical problems 
Ischemic heart disease; n (%) 573 (21) 515 (19) 514 (19) 
Heart failure; n (%) 224 (8) 217 (8) 216 (8) 
Atrial fibrillation; n (%) 638 (24) 673 (25) 684 (26) 
Chronic obstructive pulmonary disease/asthma; n (%)  253 (9) 242 (9) 245 (9) 
Other chronic lung problem; n (%) 29 (1) 24 (1) 19 (1) 
Details of the qualifying event 
Time since symptom onset; hh:mm median (IQR)
 a
  20:44 (11:53–25:33) 20:32 (12:05–25:31) 20:45 (11:57–25:31) 
Diagnosis:    
  Transient ischemic attack; n (%)
b
 52 (1.9) 50 (1.9) 66 (2.5) 
  Ischemic stroke; n (%)
b
 2187 (82.0) 2165 (81.1) 2203 (82.6) 
   Intracerebral hemorrhage; n (%)
b
   185 (6.9) 207 (7.8) 196 (7.3) 
    
  Stroke without imaging diagnosis; n (%)
b
 104 (3.9) 106 (4.0) 84 (3.1) 
  Not a stroke; n (%)
b
 101 (3.8) 98 (3.7) 93 (3.5) 
  Missing; n (%)
b
 39 (1.5) 41 (1.5) 26 (1.0) 
Glasgow Coma Scale score (3–15); median (IQR) [range] 15 (15–15) [4-15] 15 (15–15) [5-15] 15 (15–15) [3-15] 
Thrombolysed; n (%)
b
 447 (17) 410 (15) 447 (17) 
NIHSS score (0–42); median (IQR) 5 (3–9) 5 (3–9) 5 (3–9) 
Oxygenation 
Oxygen given prior to randomization; n (%)
a
  531 (20) 531 (20) 539 (20) 
Oxygen saturation on room air; % mean (SD)
 a
  96.6 (1.7) 96.6 (1.6) 96.7 (1.7) 
 586 
Data in this table were collected before randomization with the exception of items marked with b 587 
which were recorded on day 7. Minimization variables are indicated by a. Activities of daily living 588 
(ADLs). The probability of being alive and independent was calculated using the ‘six simple 589 
variables (SSV) prognostic index for independent survival at 6 months (m).20 ‘Normal verbal 590 
response’ was taken from the verbal sub-item of the Glasgow Coma Scale.  See online supplement 591 
eText 1 for definitions for diagnosis. The Glasgow Coma Scale score ranges from 3 (deep coma) to 592 
15 (alert and oriented). The National Institutes for Heath Stroke Scale ranges from 0 (no deficit) to 593 
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42 (most severe deficit). Blood glucose was converted from mm/L to mg/dl by multiplying by a 594 
factor of 18.  595 
  596 
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Table 2 Secondary, exploratory and safety outcomes  597 
 598 
 N=8003 
 (n) 
Continuous oxygen 
n=2668 
Nocturnal oxygen 
n=2667 
Control n=2668 Comparison 1: 
Combined oxygen vs. 
control 
OR, MD, MdD or RR 
(99%CI); p-value 
Comparison 2: 
Continuous vs. nocturnal  
OR, MD, MdD or RR 
(99%CI);  
p-value 
Secondary outcomes at 72 
hours 
      
Highest oxygen saturation 
(%)
a
 
7860 99.1 (99.1-99.2)  98.8 (98.7-98.9)  98.3 (98.2-98.3)  MD 0.69 (0.61-0.77); 
p<0.0001
d
 
MD 0.32 (0.22-0.41); 
p<0.0001
d
 
Lowest oxygen saturation 
(%)
a
 
7860 95.0 (94.9-95.1)  94.5 (94.4-94.6)  94.1 (94.0-94.2)  MD 0.62 (0.48-0.76); 
p<0.0001
d
 
MD 0.48 (0.32-0.63); 
p<0.0001
d
 
Oxygen saturation <90%
b
 7860 39 (1.5%)  30 (1.1%)  74 (2.8%)  OR 0.46 (0.30-0.71); 
p<0.0001
e
 
OR 1.30 (0.69-2.44); 
p=0.28
e
 
Oxygen saturation <95%
b
 7860 861 (32.9%)  1119 (42.9%)  1354 (51.5%)  OR 0.57 (0.51-0.65); 
p<0.0001
e
 
OR 0.65 (0.56-0.76); 
p=<0.0001
e
 
Need for additional oxygen
b
 7809 254 (9.8%)  209 (8.1%)  176 (6.7%)  OR 1.36 (1.07-1.73); 
p=0.0008
e
 
OR 1.23 (0.96-1.59); 
p=0.03
e
 
Secondary outcomes at 7 
days 
      
National Institutes of Health 
Stroke Scale
c
 
7778 2 (2–3)  2 (2–3)  2 (2–3)  MdD 0 (0–0);  
p=0.56
f
 
MdD 0 (0–0);  
p=0.95
f
 
Neurological improvement
b
 7778 1016 (39.2%)  1029 (39.7%)  1037 (39.9%)  OR 0.98 (0.86-1.11); 
p=0.68
e
 
OR 0.98 (0.85-1.13); 
p=0.71
e
 
Death by 7 days
b
 7959 50 (1.9%)  35 (1.3%)  45 (1.7%)  OR 0.95 (0.59-1.53); 
p=0.78
e
 
OR 1.43 (0.81-2.54); 
p=0.11
e
 
Secondary outcomes at 90 
days 
      
Death by 90 days (mRS=6) 
b
 7677 257 (10.0%)  236 (9.2%)  246 (9.7%)  OR 1.00 (0.81-1.23); 
p=0.96
e
 
OR 1.10 (0.86-1.40); 
p=0.3
e
 
Alive and independent 
(mRS≤2)b 
7677 1325 (51.6%)  1316 (51.4%)  1337 (52.5%)  OR 0.96 (0.85-1.09); 
p=0.43
e
 
OR 1.01 (0.87-1.17); 
p=0.87
e
 
Living at home
b
 6859 1961 (85.8%)  1947 (84.8%)  1947 (85.4%)  OR 0.99 (0.82-1.20); 
p=0.91
e
 
OR 1.08 (0.87-1.34); 
p=0.35
e
 
Barthel ADL index [0 
(worst)-100 (best)]
a
 
6549 70.2 (68.2-72.2)  71.1 (69.1-73.1)  70.9 (68.9-72.8)  MD -0.18 (-2.60-2.24); 
p=0.85
d
 
MD -0.86 (-3.65-1.93); 
p=0.43
d
 
Nottingham Extended ADL 
[0 (worst)–21 (best)]a 
7528 9.66 (9.29-10.02)  9.54 (9.17-9.90)  9.77 (9.40-10.14)  MD -0.17 (-0.62-0.28); 
p=0.32
d
 
MD 0.12 (-0.40-0.64); 
p=0.55
d
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600 
Table 2 continued N=8003 
 (n) 
Continuous oxygen 
n=2668 
Nocturnal oxygen 
n=2667 
Control n=2668 Comparison 1: 
Combined oxygen vs. 
control 
OR, MD, MdD or RR 
(99%CI); p-value 
Comparison 2: 
Continuous vs. nocturnal  
OR, MD, MdD or RR 
(99%CI);  
p-value 
Quality of life (EQ5D-3L) [-
0.59 (worst)-1 (best)]
a
 
7248 0.50 (0.48-0.51)  0.50 (0.48-0.51)  0.49 (0.48-0.51)  MD 0.004 (-0.02-0.03) 
p=0.71
d
 
MD 0.003 (-0.03-0.03) 
p=0.78
d
 
Quality of life (VAS) [0 
(worst)-100 (best)]
a
 
6675 55.4 (53.8-67.1)  55.7 (54.1-57.3)  55.5 (53.8-57.1)  MD 0.10 (-1.93-2.12); 
p=0.90
d
 
MD -0.24 (-2.57-2.09) 
p=0.79
d
 
Exploratory outcomes       
Highest heart rate within 72 
hours (beats per minute)
a
  
7859 87.2 (86.3-88.0)  88.0 (87.2-88.8)  87.7 (86.9-88.4)  MD -0.07 (-1.06-0.92) MD -0.83 (-2.01-0.35) 
Highest systolic BP within 
72 hours (mm Hg)
a
 
7864 162.4 (161.2-163.7)  162.8 (161.5-164.0)  164.6 (163.3-
165.8)  
MD -1.96 (-3.48-(-0.44)) MD -0.35 (-2.11-1.41) 
Highest diastolic BP within 
72 hours (mm Hg)
a
  
7861 89.5 (88.7-90.2)  90.2 (89.4-90.0)  90.9 (90.1-91.7)  MD -1.10 (-2.06- (-0.15)) MD -0.72 (-1.82-0.37) 
Highest temperature within 
7days (Celsius)
a
 
7877 37.1 (37.1-37.2)  37.2 (37.1-37.2)  37.1 (37.1-37.2)   MD 0.01 (-0.03-0.04) MD -0.01 (-0.05-0.03) 
Antibiotics given within 7 
days 
b
 
7916 400 (15.2%)  393 (14.9%)  403 (15.2%)  OR 0.99 (0.83-1.17) OR 1.02 (0.84-1.24) 
Sedatives given within 7 
days 
b
 
7916 140 (5.3%)  161 (6.1%)  154 (5.8%)  OR 0.98 (0.76-1.28) OR 0.86 (0.63-1.17) 
Sleep as good as before the 
stroke
b
 
6584 1407 (64%)  1436 (65%)  1419 (65%)  OR 0.98 (0.85-1.13) OR 0.96 (0.82-1.13) 
No significant speech 
problems
b
 
6716 1957 (88%)  1957 (87%)  1939 (87%)  OR 1.09 (0.89-1.32) OR 1.06 (0.84-1.34) 
Memory as good as before 
the stroke
b
 
6646 981 (44%)  1000 (45%)  971 (44%)  OR 1.02 (0.89-1.16) OR 0.97 (0.83-1.13) 
Safety       
Serious adverse events 
(SAEs)
a
 
8003 0.16 (0.14-0.18)  0.13 (0.11-0.16)  0.16 (0.13-0.18)  RR 0.94 (0.78-1.13); 
p=0.37
g
 
RR 1.19 (0.96-1.47); 
p=0.03
g
 
Participants with least one 
SAE
b
 
8003 348 (13.0%) 294 (11.0%) 322 (12.1%) OR 1.00 (0.83-1.20); 
p=0.96
e
 
OR 1.21 (0.97-1.51); 
p=0.02
e
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  601 
Data are given as means and 99% confidence intervals,
a
 numbers and percentages,
b
 or medians and 99% confidence intervals.
c
 Mean differences 602 
(MD) are reported for means, median differences (MdD) for medians, odds ratios (OR) for frequencies, and rate ratios (RR) for count data. ORs 603 
< 1 indicate that the outcome is less likely with oxygen than with control (reference category) in comparison 1 and less likely with continuous 604 
oxygen than with nocturnal oxygen (reference category) in comparison 2. Significance testing was by unrelated t-test
d
 chi-squared test,
e
 605 
Wilcoxon rank sum test,
f
 or negative binomial regression.g The highest and lowest oxygen saturations were the highest/lowest record of oxygen 606 
saturation on the participant’s observation chart during the 72 hours after randomization. Neurological improvement is a decrease of 4 or more or 607 
to zero on the National Institutes of Health Stroke Scale (NIHSS). Death by 90 days is a modified Rankin Scale (mRS) score of 6. Alive and 608 
independent is a modified Rankin Scale score of 2 or less. Activities of daily living (ADL), quality of life (EQ5D-3L) and visual analogue scale 609 
(VAS). As outlined in the statistical analysis plan,
17 
 significance tests were not conducted on the exploratory data and the outcomes suggested 610 
by patients and carers. HR: heart rate. 611 
 612 
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FIGURE LEGENDS  613 
 614 
Figure 1 Trial profile 615 
This figure shows participant enrollment, withdrawals, and follow up. Data on the number of 616 
patients screened are not available.  617 
 618 
Figure 2 Main outcome: modified Rankin Scale at 90 days 619 
 620 
From the ordinal regression analysis the unadjusted odds ratio (OR) for a better outcome 621 
(lower mRS) was 0.97 (95% CI 0.89–1.05, p=0.47) for combined oxygen versus control, and 622 
1.03 (95% CI 0.93–1.13, p=0.61) for continuous oxygen versus nightly oxygen. Modified 623 
Rankin Scale (mRS): 0 = no symptoms, 1=few symptoms, but able to carry out all previous 624 
activities and duties, 2 = unable to carry out all previous activities, but able to look after own 625 
affairs without assistance, 3 = needs some help with looking after own affairs, but able to 626 
walk without assistance, 4 = unable to walk without assistance and unable to attend to own 627 
bodily needs without assistance, but I does not need constant care and attention, 5 = major 628 
symptoms (bedridden and incontinent, needs constant attention day and night), 6 = death. 629 
Figure 3 Subgroup analyses: mRS at 90 days oxygen versus control 630 
 631 
Subgroup analyses are depicted as a forest plot; p-values relate to the test for interaction. The 632 
x-axis depicts the ‘common’ odds ratio (OR) for a better outcome over all 7 levels of the 633 
modified Rankin Scale score (mRS). It is derived from ordinal logistic regression. ORs > 1 634 
indicate that a good outcome (low mRS) is more likely with oxygen than with control 635 
(reference category). n is the total number of participants in that subgroup category. The size 636 
of the markers reflects the total sample size in the subgroup concerned, with larger markers 637 
equating to more precise estimates. The subgroup thresholds for oxygen concentration at 638 
randomization were revised from the prespecified thresholds as the analysis did not converge 639 
using the prespecified values. NIHSS: National Institutes of Health Stroke Scale; TIA: 640 
transient ischemic attack; SSV: ‘six simple variables’ risk score; COPD: chronic obstructive 641 
pulmonary disease; CCF: congestive cardiac failure; GCS: Glasgow Coma Scale.  642 
Figure 4 Mortality up to 90 days  643 
 644 
This figure shows the probability of death in the control group (grey dashed line) and the 645 
combined oxygen group (black line) in the top panel. The bottom panel shows the probability 646 
of death in the nocturnal oxygen group (dashed grey line) and the probability of death in the 647 
continuous oxygen group (black line). The cut off for mortality for this figure was 90 days. 648 
This is different from the 90-day mortality reported in table 2 and Figure 2, where responses 649 
were accepted up to 6 months if 3-month outcomes were not returned. Median and [range] of 650 
duration of follow-up was 90 days [0-90] in each treatment group.  651 
  
 
Figure 1 
8003 enrolled 
8003 randomized 
2668 assigned continuous oxygen 2667 assigned nocturnal oxygen 2668 assigned control 
 Assessed at 7 days (n= 2651) 
  Lost to follow-up (n= 1) 
  Withdrawn (n= 16) 
  Reasons given for withdrawal: 
- withdrawn consent (n=9) 
- patient did not like treatment (n=5) 
- did not state reason (n=1) 
- other (n=1) 
 Assessed at 7 days (n= 2646) 
  Lost to follow-up (n= 1) 
  Withdrawn (n=20) 
  Reasons given for withdrawal: 
- withdrawn consent (n=8) 
- patient did not like treatment (n=4) 
- did not state reason (n=1) 
- other (n=7) 
 Assessed at 7 days (n= 2664) 
  Lost to follow-up (n= 0) 
  Withdrawn (n=4) 
  Reasons given for withdrawal: 
- withdrawn consent (n=2) 
- patient did not like treatment (n=0) 
- did not state reason (n=1) 
- other (n=1) 
 Assessed at 90 days (n= 2576) 
  Lost to follow-up (n= 35) 
  Withdrew from follow-up  (n=40)            
  Reasons given for withdrawal: 
- withdrawn consent (n=25) 
- patient did not like treatment (n=0) 
- patient left country (n=0) 
- did not state reason (n=5) 
- not a stroke (n=3) 
- patient not well (n=4) 
- other (n=3) 
 Assessed at 90 days (n= 2576) 
  Lost to follow-up (n= 27) 
  Withdrew from follow-up  (n=43) 
  Reasons given for withdrawal: 
- withdrawn consent (n=26) 
- patient did not like treatment (n=1) 
- patient left country (n=1) 
- did not state reason (n=5) 
- not a stroke (n=2) 
- patient not well (n=5) 
- other (n=3) 
 Assessed at 90 days (n= 2567) 
  Lost to follow-up (n= 44) 
  Withdrew from follow-up  (n=53) 
  Reasons given for withdrawal: 
- withdrawn consent (n=23) 
- patient did not like treatment (n=0) 
- patient left country (n=0) 
- did not state reason (n=8) 
- not a stroke (n=5) 
- patient not well (n=3) 
- other (n=14) 
 Included in the analysis of the primary 
outcome (n=2561) 
 
Missing data for primary outcome (n=15) 
 
 
   
Included in the analysis of the primary 
outcome (n=2549) 
 
 Missing data for primary outcome (n=18) 
 
 Included in the analysis of the primary 
outcome (n=2567) 
 
Missing data for primary outcome (n=9) 
   
 
 
Figure 2  
Comparison 1: Combined oxygen vs. control p-value 
 
0.47 
 
   
Comparison 2: Continuous oxygen vs. nocturnal oxygen   
 
 
 
 
 
 
 
 
 
 
 
 
0.61 
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NIHSS at Baseline
0−4
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Ischemic Stroke
TIA
Primary intracerebral hemorrhage
Stroke without imaging diagnosis
Other
Time Since Stroke Onset
≤ 3 hours
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> 24 hours
Age at Randomization
<50 years
50−80 years
>80 years
SSV Risk Score
SSV ≤ 0.1
SSV > 0.1− ≤ 0.35
SSV > 0.35− ≤ 0.7
SSV > 0.7
COPD Status
No COPD
COPD
Heart Failure
No CCF
CCF
Level of Consciousness
GCS eye and motor score <10
GCS eye and motor score =10
Oxygen before Randomization
No Oxygen
Oxygen
Thrombolysis Performed
No Thrombolysis
Thrombolysis
All Patients
145
333
3074
1576
2269
1619
636
354
250
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381
205
178
71
399
823
2142
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1.00 (0.74−1.36)
1.02 (0.64−1.60)
0.82 (0.52−1.31)
0.92 (0.43−1.95)
0.84 (0.63−1.12)
1.13 (0.91−1.39)
0.95 (0.83−1.08)
0.95 (0.82−1.10)
0.97 (0.69−1.36)
0.95 (0.86−1.06)
0.99 (0.85−1.15)
1.05 (0.88−1.24)
0.86 (0.71−1.03)
1.05 (0.90−1.23)
0.89 (0.75−1.05)
0.99 (0.91−1.08)
0.79 (0.60−1.04)
0.98 (0.90−1.07)
0.92 (0.69−1.24)
0.97 (0.76−1.25)
0.97 (0.89−1.06)
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